Active Ingredient History
Nimodipine is a dihydropyridine calcium antagonist which has been shown to dilate cerebral arterioles and increase cerebral blood flow in animals and humans. It has potential in the treatment of a range of cerebrovascular disorders. Major interest to date, however, has focused on its use in the prevention and treatment of the delayed ischaemic neurological deficits that frequently occur in patients with subarachnoid haemorrhages as a result of sustained cerebral vasospasm. Nimodipine, a Ca2+ antagonist with cerebrovasodilatory and anti-ischemic effects, binds to rat, guinea pig, and human brain membranes with high affinity (less than 1 nM). Only at higher concentrations has nimodipine been reported to block the release of some neurotransmitters and hormones from neuronal tissue. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Subarachnoid Hemorrhage (approved 2013)
AIDS Dementia Complex (Phase 1)
Aneurysm (Phase 1/Phase 2)
Biological Availability (Early Phase 1)
Catheterization (Phase 4)
Cerebral Infarction (Phase 4)
Cerebrovascular Disorders (Early Phase 1)
Cocaine-Related Disorders (Phase 2)
Cognitive Dysfunction (Phase 4)
Coronary Vasospasm (Phase 2)
Delirium (Phase 2)
Dementia (Phase 4)
Depression (Phase 4)
Drugs, Investigational (Phase 2)
Electroconvulsive Therapy (Phase 2)
Epilepsy (Phase 2)
HIV Infections (Phase 1)
Infertility (Phase 2)
Milrinone (Phase 2)
Mutation (Phase 1)
Neuroma, Acoustic (Phase 2)
Poisoning (Phase 3)
Schizophrenia (Early Phase 1)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 3)
Traumatology (Phase 2)
Ultrasonography (Early Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue